In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine

Oncology Reports

Volumn 5, Issue 6, 1998, Pages 1493-1498

  Obrocea, Mihail M ^a   Nassim, Mark Adel ^b   Molepo, Matshela J ^c   Shirazi, Farshad H ^b   Gallant, Gilles ^d   Dulude, Hélène ^d   Vincent, Mark D ^e   Stewart, David J ^b   Goel, Rakesh ^b  

^a Lahey Hitchcock Clinic   (United States)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c UNIVERSITY OF VENDA   (South Africa)

^d BRISTOL MYERS SQUIBB   (United States)

^e LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Carboplatin; HPLC; Mesna

Indexed keywords

CARBOPLATIN; MESNA;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG INTERACTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; URINE;

EID: 0031662476     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.6.1493     Document Type: Article

References (28)

1. Calvert AH, Newell DR and Gore ME: Future directions with carboplatin: can therapeutic monitoring, high-dose administration, and hematologic support with growth factors expand the spectrum compared with cisplatin. Semin Oncol 19 (Suppl 2): 155-163, 1992.
2. Canneta R, Rozencweig M and Carter SK: Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12: 125-136, 1985.
3. Dorr TR and Lagel K: Interaction between cisplatin and mesna in mice. J Cancer Res Clin Oncol 115: 604-605, 1989.
4. 14C]-mercaptoethanesulphonate in the rat. Arzneimittelforschune 36: 487-489, 1986.
5. Siddik ZH, Jones M, Boxall FE and Harrap KR: Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 21: 19-24, 1988.
6. Fukoka M, Negoro S, Masuda N, Furuse K, Kawahara M, Kodama N, Ikegami H, Nakamura S, Nishio H and Ohnoshi T: Placebo-controlled double blind study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 117: 473-478, 1991.
7. Goel R, Cleary SM, Horton CA, Kirmani S and Abramson I: Effect of sodium thiosulphate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst 81: 1552-1560, 1989.
8. Leeuwenkamp OR, Neijt JP, van der Vijgh WJF and Pinedo HM: Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di) mesna and thiosulphate. Eur J Cancer 27: 1243-1247, 1991.
9. Turill M, Spicer DV, Kelley AS, Herman RL, Russell CA and Muggia FM: Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma. Cancer Invest 13: 160-164, 1995.
10. Hsieh RK, Chang AY, Boros L and Asbury R: Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer. Am J Clin Oncol 17: 509-513, 1994.
11. Steger GG, Dittrich C and Schlappack O: Toxicity and response to high dose ifosfamide and mesna as salvage therapy for advanced breast cancer. J Cancer Res Clin Oncol 114: 602-604, 1988.
12. Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K and Smyht R: Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 28: 208-215, 1988.
13. Margolin BK, Doroshow JH, Ahn C, Hamasaki V, Leong L, Morgan R, Raschko J, Shibata S, Somlo G and Tetef M: Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stemcell. J Clin Oncol 14: 2631-2637, 1996.
14. De Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R. Testa N and Thatcher N: Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 13: 1623-1631, 1995.
15. Martino S, Sanal BA and Sighahako A: A phase II study of cis-diammine-dichloroplatinum II for advanced breast cancer: two dose schedules. J Cancer Res Clin Oncol 108: 354-356, 1984.
16. Palackdharry CS: Phase 1 trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: prelimiary results. Semin Oncol 23 (Suppl 6): 78-83, 1996.
17. Postmus PE, Scagliotti G, Groen HJ, Gozzelino F, Burghouts JT, Curran D, Sahoud T, Kirkpatrick A, Giaccone G and Splinter TA: Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC phase III trial. Eur J Cancer 32A: 1498-1503, 1996.
18. Duncan GF, Faulkner HC III, Farmen RH and Pittman KA: Liquid chromatographic procedure for quantitative analysis of carboplatin in beagle dog plasma ultra filtrate. J Pharmacol Sci 77: 273-276, 1988.
19. Gaver RC and Deeb G: High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine. Cancer Chemother Pharmacol 16: 201-206, 1986.
20. James CA, Mant TJK and Rogers HJ: Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol 23: 561-568, 1987.
21. Harland SJ, Newell DR, Siddik ZH, Chadwick R and Calvert AH: Pharmacokinetics of cis-diammine-1,1 -cyclobutanedicarboxilate platinum (II) in patients with normal and impaired renal function. Cancer Res 44: 1693-1697, 1984.
22. 14C-carboplatin. Cancer Chemother Pharmacol 20: 271-276, 1987.
23. Sorensen BT, Stromgren A, Jakobsen P, Nielsen JT, Andersen LS and Jakobsen A: Renal handling of carboplatin. Cancer Chemother Pharmacol 30: 317-320, 1992.
24. Erkman K, Egorin MJ, Reyno LM. Morgan R and Doroshaw JH: Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother Pharmacol 35: 254-256, 1995.
25. Momburgh R, Bourdeaux M, Sarrazin M, Roux F and Brian C: In vitro plasma binding of some second generation antitumor platinum complexes. Eur J Drus Metab Pharmacokinet 10: 77-83, 1985.
26. Van der Vijgh WJK and Klein I: Protein binding of five platinum compounds. Comparison of two ultrafiltration systems. Cancer Clin Oncol 18: 129-132, 1986.
27. Ganong WP: Regulation of extracellular fluid composition and volume. In: Medical Physiology Appleton and Lange. Conneticut, pp663-672, 1995.
28. Gibaldi M: Drug disposition. In: Biopharmaceutics and Clinical Pharmacokinetics. Lea & Febiger, Philadelphia, pp83-107, 1977.